secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anika Therapeutics, Inc. (ANIK)
CIK:        0000898437
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0001171843-23-003096
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anika Q1 revenue up 3% to $37.9M but net loss widens to $10.4M
--------------------------------------------------------------

- OA Pain Mgmt rev $22.6M (+8% YoY); Joint Preservation & Restoration rev $13.5M (+11% YoY).
- Net loss ($10.4M) or ($0.71)/share; adjusted net loss ($5.3M) or ($0.36)/share.
- Adj EBITDA ($1.2M) vs +$2.6M in Q1 2022; gross margin 60% (adj 64%).
- FY 2023 rev guidance reaffirmed at $158-163M; $20M share buyback authorized.
- Post-quarter: settled Parcus arbitration, cooperation with Caligan, added director Fischetti.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/898437/000117184323003096/0001171843-23-003096-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/898437/000117184323003096/f8k_050923.htm
  HTML page:      https://secwatch.observer/filing/0001171843-23-003096

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer